$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000201 Filed on March 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$9.786M	$8.668M	$36.35M
YoY Change	3.56%	-7.69%	4.79%
Cost Of Revenue	$3.216M	$3.357M	$13.96M
YoY Change	-19.49%	-7.61%	0.01%
Gross Profit	$6.571M	$5.311M	$22.39M
YoY Change	20.44%	-7.74%	8.0%
Gross Profit Margin	67.14%	61.27%	61.6%
Selling, General & Admin	$8.567M	$10.10M	$36.94M
YoY Change	1.23%	18.69%	7.72%
% of Gross Profit	130.39%	190.09%	164.95%
Research & Development	$2.248M	$4.097M	$15.73M
YoY Change	-46.65%	20.42%	4.03%
% of Gross Profit	34.22%	77.13%	70.24%
Depreciation & Amortization	$397.3K	$394.6K	$1.462M
YoY Change	53.61%	76.8%	112.39%
% of Gross Profit	6.05%	7.43%	6.53%
Operating Expenses	$11.50M	$14.19M	$52.67M
YoY Change	-13.87%	19.18%	0.79%
Operating Profit	-$4.926M	-$8.881M	-$30.27M
YoY Change	-37.59%	39.73%	-3.96%
Interest Expense	-$6.653K	$2.631M	$1.791M
YoY Change	-89.47%	-42.45%	1250.99%
% of Operating Profit
Other Income/Expense, Net	-$1.432M	$61.75K	$96.75K
YoY Change	-353.19%	-183.3%	-104.06%
Pretax Income	-$6.358M	-$6.649M	-$29.32M
YoY Change	-13.21%	257.7%	-13.52%
Income Tax		-$813.7K	-$813.7K
% Of Pretax Income
Net Earnings	-$6.358M	-$5.835M	-$28.51M
YoY Change	-13.21%	661.61%	-13.12%
Net Earnings / Revenue	-64.97%	-67.31%	-78.43%
Basic Earnings Per Share	-$0.12	-$0.12	-$0.64
Diluted Earnings Per Share	-$0.12	-$0.13	-$0.64
COMMON SHARES
Basic Shares Outstanding	54.29M	44.44M	44.66M
Diluted Shares Outstanding	54.26M		44.66M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.608M	$14.13M	$14.13M
YoY Change	-54.81%	-36.19%	-36.19%
Cash & Equivalents	$8.608M	$14.13M	$14.13M
Short-Term Investments
Other Short-Term Assets	$880.4K	$1.834M	$1.834M
YoY Change	-52.75%	-26.28%	-26.28%
Inventory	$3.739M	$3.680M	$3.680M
Prepaid Expenses
Receivables	$6.765M	$6.057M	$6.057M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.99M	$25.70M	$25.70M
YoY Change	-29.02%	-23.87%	-23.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.749M	$22.12M	$22.12M
YoY Change	-8.85%	105.86%	-5.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.920M	$5.443M	$1.536M
YoY Change	-11.82%	22.65%	-11.44%
Total Long-Term Assets	$27.08M	$27.56M	$27.56M
YoY Change	-7.58%	-6.49%	-6.49%
TOTAL ASSETS
Total Short-Term Assets	$19.99M	$25.70M	$25.70M
Total Long-Term Assets	$27.08M	$27.56M	$27.56M
Total Assets	$47.07M	$53.26M	$53.26M
YoY Change	-18.09%	-15.77%	-15.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.399M	$3.802M	$3.802M
YoY Change	-19.88%	129.71%	129.71%
Accrued Expenses	$6.929M	$6.667M	$6.682M
YoY Change	18.98%	683.73%	42.72%
Deferred Revenue		$1.381M
YoY Change		-8.96%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.500M	$2.500M	$2.500M
YoY Change
Total Short-Term Liabilities	$13.42M	$14.55M	$14.55M
YoY Change	28.63%	49.73%	49.73%
LONG-TERM LIABILITIES
Long-Term Debt	$1.929M	$2.543M	$2.543M
YoY Change	-61.51%	-49.14%	-49.14%
Other Long-Term Liabilities	$12.79M	$12.90M	$12.90M
YoY Change	-2.07%	-1.87%	-1.87%
Total Long-Term Liabilities	$1.929M	$15.44M	$15.44M
YoY Change	-89.33%	208.79%	-14.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.42M	$14.55M	$14.55M
Total Long-Term Liabilities	$1.929M	$15.44M	$15.44M
Total Liabilities	$28.14M	$29.99M	$29.99M
YoY Change	-1.28%	7.64%	7.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$288.9M	-$282.5M
YoY Change	10.54%	11.22%
Common Stock	$54.29K	$54.24K
YoY Change	23.81%	24.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.93M	$23.28M	$23.28M
YoY Change
Total Liabilities & Shareholders Equity	$47.07M	$53.26M	$53.26M
YoY Change	-18.09%	-15.77%	-15.77%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.358M	-$5.835M	-$28.51M
YoY Change	-13.21%	661.61%	-13.12%
Depreciation, Depletion And Amortization	$397.3K	$394.6K	$1.462M
YoY Change	53.61%	76.8%	112.39%
Cash From Operating Activities	-$4.830M	-$6.407M	-$21.66M
YoY Change	55.39%	19.98%	-23.3%
INVESTING ACTIVITIES
Capital Expenditures	$45.19K	$135.9K	$936.2K
YoY Change	-91.13%	-34.04%	-84.62%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$127.0K	-$135.9K	-$936.2K
YoY Change	-81.4%	-34.04%	-85.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.47M
YoY Change
Debt Paid & Issued, Net	$625.0K
YoY Change
Cash From Financing Activities	-571.8K	12.21M	14.47M
YoY Change	-183.56%	144.21%	191.84%
NET CHANGE
Cash From Operating Activities	-4.830M	-6.407M	-21.66M
Cash From Investing Activities	-127.0K	-135.9K	-936.2K
Cash From Financing Activities	-571.8K	12.21M	14.47M
Net Change In Cash	-5.523M	5.667M	-8.117M
YoY Change	78.37%	-1137.18%	-72.94%
FREE CASH FLOW
Cash From Operating Activities	-$4.830M	-$6.407M	-$21.66M
Capital Expenditures	$45.19K	$135.9K	$936.2K
Free Cash Flow	-$4.875M	-$6.543M	-$22.59M
YoY Change	34.75%	17.97%	-34.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2021	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2021	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2022	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2022	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2022	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2023	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2023	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2023	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q2	ctso	Defined Contribution Eligibility Term DefinedContributionEligibilityTerm	P3M
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36792
CY2023	dei	Entity Registrant Name EntityRegistrantName	CYTOSORBENTS CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0373793
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	305 College Road East
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
CY2023	dei	City Area Code CityAreaCode	732
CY2023	dei	Local Phone Number LocalPhoneNumber	329-8885
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	CTSO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	143849000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54293555
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14131137
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22144567
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	49663
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	76041
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6057072
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5664941
CY2023Q4	us-gaap	Inventory Net InventoryNet	3680129
CY2022Q4	us-gaap	Inventory Net InventoryNet	3461586
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1834485
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2488597
CY2023Q4	us-gaap	Assets Current AssetsCurrent	25702823
CY2022Q4	us-gaap	Assets Current AssetsCurrent	33759691
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10056354
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10743032
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1483958
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1687459
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12058896
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12603901
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3958603
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4437447
CY2023Q4	us-gaap	Assets Assets	53260634
CY2022Q4	us-gaap	Assets Assets	63231530
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3802170
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1655173
CY2023Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	7870149
CY2022Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	7950440
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	373636
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108939
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2500000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14545955
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9714552
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12896659
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13142005
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2542857
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5000000
CY2023Q4	us-gaap	Liabilities Liabilities	29985471
CY2022Q4	us-gaap	Liabilities Liabilities	27856557
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54240265
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54240265
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43635715
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43635715
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	54240
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	43635
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305196874
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	287000021
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	529321
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2329195
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-282505272
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253997878
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	23275163
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35374973
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53260634
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63231530
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	36349379
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34688809
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	43165527
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13957356
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13955752
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11047350
CY2023	us-gaap	Gross Profit GrossProfit	22392023
CY2022	us-gaap	Gross Profit GrossProfit	20733057
CY2021	us-gaap	Gross Profit GrossProfit	32118177
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15728915
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15118907
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16380930
CY2023	us-gaap	Professional Fees ProfessionalFees	4272296
CY2022	us-gaap	Professional Fees ProfessionalFees	2847899
CY2021	us-gaap	Professional Fees ProfessionalFees	2731515
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33600065
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34288130
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35750477
CY2023	us-gaap	Operating Expenses OperatingExpenses	53601276
CY2022	us-gaap	Operating Expenses OperatingExpenses	52254936
CY2021	us-gaap	Operating Expenses OperatingExpenses	54862922
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-31209253
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-31521879
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-22744745
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-157891
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	132597
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	28007
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1949257
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2448583
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2577913
CY2023	ctso	Miscellaneous Income Expense MiscellaneousIncomeExpense	96754
CY2022	ctso	Miscellaneous Income Expense MiscellaneousIncomeExpense	-67303
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1888120
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2383289
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2549906
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29321133
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33905168
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25294651
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-813739
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1092585
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-736003
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28507394
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32812583
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24558648
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44656391
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44656391
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43573215
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43573215
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43359186
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43359186
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28507394
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32812583
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24558648
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1799874
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1803610
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2259663
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30307268
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31008973
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22298985
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79215579
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4020819
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-90000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-52678
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	135857
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1623580
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	928417
CY2021	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	805199
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-2832
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2259663
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24558648
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62578197
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3423517
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	40358
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	380091
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1803610
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	42499
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32812583
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35374973
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3329307
CY2023	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	218278
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14255934
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	403939
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1799874
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28507394
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	23275163
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28507394
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32812583
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24558648
CY2023	ctso	Accrued Final Fee AccruedFinalFee	42857
CY2023	ctso	Noncash Expense NoncashExpense	371397
CY2022	ctso	Noncash Expense NoncashExpense	376574
CY2021	ctso	Noncash Expense NoncashExpense	2183317
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1462436
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	882621
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	731578
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	564356
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	249008
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	398035
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14434
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-8354
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-512
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-132303
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	655685
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	635606
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1949256
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2448583
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2577913
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3329307
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3423517
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4020819
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	245616
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1288422
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-420578
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	121039
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-945352
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2350547
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1104167
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22187
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-280915
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	50
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3248978
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2426810
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21655136
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28234282
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14005599
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	538115
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6087365
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3641248
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	398121
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	368211
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	640013
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-936236
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6455576
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4281261
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000
CY2023	ctso	Payments For Equity Contributions Net Of Fees Incurred PaymentsForEquityContributionsNetOfFeesIncurred	-14255932
CY2022	ctso	Payments For Equity Contributions Net Of Fees Incurred PaymentsForEquityContributionsNetOfFeesIncurred	40358
CY2021	ctso	Payments For Equity Contributions Net Of Fees Incurred PaymentsForEquityContributionsNetOfFeesIncurred	90000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	218278
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	805199
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14474210
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4959642
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	715199
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-99769
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-262924
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-24774
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8216931
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29993140
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17596435
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23832026
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53825166
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71421601
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15615095
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23832026
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53825166
CY2023	us-gaap	Interest Paid Net InterestPaidNet	376668
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	42499
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	359965
CY2023	us-gaap	Stock Issued1 StockIssued1	403939
CY2022	us-gaap	Stock Issued1 StockIssued1	380091
CY2021	us-gaap	Stock Issued1 StockIssued1	928417
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. BASIS OF PRESENTATION:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents Medical Inc., its wholly owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly owned European subsidiary (the “European Subsidiary”). In addition, the consolidated financial statements include CytoSorbents Switzerland, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited, and CytoSorbents France SAS, the wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited and CytoSorbents India Private Limited, wholly-owned subsidiaries of CytoSorbents Medical, Inc. These entities are collectively referred to as the “Company”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2023, the Company’s total cash and cash equivalents were approximately $15.6 million, including approximately $14.1 million in cash and cash equivalents and approximately $1.5 million in restricted cash, which is not expected to fund the Company’s operations beyond the next twelve months from the issuance of these consolidated financial statements. This matter raises substantial doubt about the Company’s ability to continue as a going concern. As a result, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is actively pursuing financing sources, including less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors.</p>
CY2023Q4	ctso	Cash And Cash Equivalents Gross Value CashAndCashEquivalentsGrossValue	15600000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14100000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1500000
CY2023	ctso	Number Of Countries Where Flagship Product Is Marketed And Distributed NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed	75
CY2022Q2	ctso	Supplier Agreement Term SupplierAgreementTerm	P3Y
CY2022Q2	ctso	Number Of Healthcare Facilities NumberOfHealthcareFacilities	170
CY2022Q2	ctso	Number Of States Across Healthcare Facilities NumberOfStatesAcrossHealthcareFacilities	14
CY2023Q4	ctso	Number Of Patents United States NumberOfPatentsUnitedStates	19
CY2023	ctso	Foreign Currency Transaction Gain Loss Excluding Tax ForeignCurrencyTransactionGainLossExcludingTax	1949000
CY2022	ctso	Foreign Currency Transaction Gain Loss Excluding Tax ForeignCurrencyTransactionGainLossExcludingTax	-2449000
CY2021	ctso	Foreign Currency Transaction Gain Loss Excluding Tax ForeignCurrencyTransactionGainLossExcludingTax	-2578000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14131137
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22144567
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1483958
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1687459
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15615095
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23832026
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1483958
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1687459
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2155457
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1567871
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	838871
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1280368
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	685801
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	613347
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	ctso	Wrote Off Patents Costs WroteOffPatentsCosts	656000
CY2022	ctso	Wrote Off Patents Costs WroteOffPatentsCosts	636000
CY2023	us-gaap	Advertising Expense AdvertisingExpense	253000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	582000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	615000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2100000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for credit losses and recoverability of patents are significant estimates in these consolidated financial statements.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured CashSweep (“ICS”) account whereby all cash that was previously held in the Company’s money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFi’s 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A significant portion of the Company’s revenues are from product sales in Germany. Substantially all of the Company’s grant and other income are from grant agencies in the United States. (See Note 3 for further information relating to the Company’s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivables. As of December 31, 2022, two distributors accounted for approximately 27% of outstanding grants and accounts receivables. For the years ended December 31, 2023, 2022 and 2021, no agency, distributor/strategic partner or direct customer represented more than 10% of the Company’s total revenue.</p>
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	36349379
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34688809
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	43165527
CY2023	ctso	Number Of Primary Revenue Streams NumberOfPrimaryRevenueStreams	2
CY2023	ctso	Term Of Customer Contracts TermOfCustomerContracts	P3Y
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	3846271
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	3822452
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	1577141
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	1694906
CY2022Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	3000708
CY2023Q4	ctso	Contract With Customer Liability Value Of Free Of Charge Goods And Credit Rebates Current ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent	196322
CY2022Q4	ctso	Contract With Customer Liability Value Of Free Of Charge Goods And Credit Rebates Current ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent	178134
CY2023Q4	ctso	Contract With Customer Liability Net Of Free Of Charge Goods And Credit Rebates Current ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent	1376819
CY2022Q4	ctso	Contract With Customer Liability Net Of Free Of Charge Goods And Credit Rebates Current ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent	1516772
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	2251177
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13092384
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12639724
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3036030
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1896692
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10056354
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10743032
CY2023	us-gaap	Depreciation Depreciation	1239600
CY2022	us-gaap	Depreciation Depreciation	688565
CY2021	us-gaap	Depreciation Depreciation	571156
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1021233
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	848999
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3906552
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4390533
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	52051
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	46914
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3958603
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4437447
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	222836
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	194056
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	160422
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	218000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	218000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	217000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	212000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	212000
CY2023Q4	ctso	Accrued Salaries And Commissions Current AccruedSalariesAndCommissionsCurrent	3344080
CY2022Q4	ctso	Accrued Salaries And Commissions Current AccruedSalariesAndCommissionsCurrent	2862930
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1380821
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1516772
CY2023Q4	ctso	Clinical Study Costs Payable Current ClinicalStudyCostsPayableCurrent	956432
CY2022Q4	ctso	Clinical Study Costs Payable Current ClinicalStudyCostsPayableCurrent	1115123
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	497627
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	850630
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	686908
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	622353
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	513338
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	592398
CY2023Q4	ctso	Customer Rebates CustomerRebates	181284
CY2022Q4	ctso	Customer Rebates CustomerRebates	166065
CY2023Q4	ctso	Accrued Travel And Entertainment Expense Current AccruedTravelAndEntertainmentExpenseCurrent	134182
CY2022Q4	ctso	Accrued Travel And Entertainment Expense Current AccruedTravelAndEntertainmentExpenseCurrent	99316
CY2023Q4	ctso	Accrued Director Fees Current AccruedDirectorFeesCurrent	84610
CY2022Q4	ctso	Accrued Director Fees Current AccruedDirectorFeesCurrent	97426
CY2023Q4	ctso	Sales Payroll And Income Taxes Payable Current SalesPayrollAndIncomeTaxesPayableCurrent	56423
CY2022Q4	ctso	Sales Payroll And Income Taxes Payable Current SalesPayrollAndIncomeTaxesPayableCurrent	21871
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	34444
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5556
CY2023Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	7870149
CY2022Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	7950440
CY2023	ctso	Debt Instrument Non Refundable Fee Upon Termination Or Maturity Percent DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent	0.025
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5000000
CY2023	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	42857
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	5042857
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2500000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2542857
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2500000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2500000
CY2023Q4	ctso	Long Term Debt And Final Fee LongTermDebtAndFinalFee	5000000
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.098
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12058896
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12603901
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13270295
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13250944
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	373636
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108939
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12896659
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13142005
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1656678
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1695677
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1735747
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1776920
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1819224
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	15413075
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24097321
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10827026
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13270295
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2403000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2935000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1968000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y4M24D
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21475931
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21155203
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18829797
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7843202
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-12749965
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6464854
CY2023	ctso	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interests IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests	-29319133
CY2022	ctso	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interests IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests	-33905168
CY2021	ctso	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interests IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests	-25294651
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-813739
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-1092585
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-736003
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-813739
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1092585
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-736003
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47700000
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	80% limitation on taxable
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2100000
CY2023	ctso	Proceeds From Sale Of Net Operating Loss Carryforwards ProceedsFromSaleOfNetOperatingLossCarryforwards	816000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36836007
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31570846
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27190654
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	418776
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	500975
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1203272
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2310639
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3982147
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2687591
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	248673
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	24121
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	232665
CY2023Q4	ctso	Deferred Tax Assets Tax Credit Carryforwards Lease Liability DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability	3730280
CY2022Q4	ctso	Deferred Tax Assets Tax Credit Carryforwards Lease Liability DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability	3724840
CY2021Q4	ctso	Deferred Tax Assets Tax Credit Carryforwards Lease Liability DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability	3997114
CY2023Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	5495850
CY2022Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	3331625
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49040225
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43134554
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35311296
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45334554
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39303451
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31242130
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3705671
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3831103
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4069166
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	315915
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	288145
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	183941
CY2023Q4	ctso	Deferred Tax Liabilities Rights Of Use Assets DeferredTaxLiabilitiesRightsOfUseAssets	3389756
CY2022Q4	ctso	Deferred Tax Liabilities Rights Of Use Assets DeferredTaxLiabilitiesRightsOfUseAssets	3542958
CY2021Q4	ctso	Deferred Tax Liabilities Rights Of Use Assets DeferredTaxLiabilitiesRightsOfUseAssets	3885225
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6031103
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8061321
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6447656
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.052
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.028
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.023
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.034
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.023
CY2023	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.020
CY2022	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.015
CY2021	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.065
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.118
CY2023	ctso	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	-0.072
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.206
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.228
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.255
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.019
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.017
CY2023	ctso	Effective Income Tax Rate Reconciliation Sale Of Research And Development Tax Credit And Net Operating Loss Percent EffectiveIncomeTaxRateReconciliationSaleOfResearchAndDevelopmentTaxCreditAndNetOperatingLossPercent	0.028
CY2022	ctso	Effective Income Tax Rate Reconciliation Sale Of Research And Development Tax Credit And Net Operating Loss Percent EffectiveIncomeTaxRateReconciliationSaleOfResearchAndDevelopmentTaxCreditAndNetOperatingLossPercent	0.032
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.028
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.032
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.028
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1842332
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	270901
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2113233
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019Q1	ctso	Executive Employment Agreements Initial Term ExecutiveEmploymentAgreementsInitialTerm	P3Y
CY2022Q1	ctso	Employment Agreements Automatic Renewal Period EmploymentAgreementsAutomaticRenewalPeriod	P1Y
CY2022Q1	ctso	Employment Agreements Automatic Renewed Period EmploymentAgreementsAutomaticRenewedPeriod	P1Y
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	280000
CY2023	ctso	Royalty Payments For Interest RoyaltyPaymentsForInterest	0.009
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	ctso	Aggregate Registered Amount For Offerings AggregateRegisteredAmountForOfferings	150000000
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0
CY2023Q4	ctso	Number Of Long Term Incentive Plans NumberOfLongTermIncentivePlans	2
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3329000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3424000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4021000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5165204
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.36
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2051980
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.78
CY2021	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	138037
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.73
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	21756
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.46
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	171413
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.73
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6885978
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.09
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4086205
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.97
CY2022	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y7M9D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1270155
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.65
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	227204
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.71
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9474824
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.66
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2601880
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.43
CY2023	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y6M7D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	974555
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.96
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	467332
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.61
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	86643
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.59
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10548174
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.49
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.11
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5342438
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.97
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4851739
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.84
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2601880
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	974555
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.95
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1273328
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.59
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5205736
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.89
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4868000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P42M
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	260000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	19504184
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	11359928
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	4480275
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	3134085
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2706561
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.00
CY2014Q2	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.20
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	405000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	442000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	355000
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9449496
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9420821
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8810847
CY2023Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8668215
CY2023Q1	us-gaap	Gross Profit GrossProfit	5455327
CY2023Q2	us-gaap	Gross Profit GrossProfit	6018550
CY2023Q3	us-gaap	Gross Profit GrossProfit	5606866
CY2023Q4	us-gaap	Gross Profit GrossProfit	5311280
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7891596
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6559237
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7350198
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9408222
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7325883
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6153084
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9193520
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5834907
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8691424
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8495558
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8111353
CY2022Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9390474
CY2022Q1	us-gaap	Gross Profit GrossProfit	6413788
CY2022Q2	us-gaap	Gross Profit GrossProfit	4944856
CY2022Q3	us-gaap	Gross Profit GrossProfit	3617377
CY2022Q4	us-gaap	Gross Profit GrossProfit	5757036
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7791135
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8357050
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9017338
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6356356
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8966398
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10879222
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12200837
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-766128
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10598847
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12024069
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9760416
CY2021Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10782195
CY2021Q1	us-gaap	Gross Profit GrossProfit	7847403
CY2021Q2	us-gaap	Gross Profit GrossProfit	9313852
CY2021Q3	us-gaap	Gross Profit GrossProfit	7297470
CY2021Q4	us-gaap	Gross Profit GrossProfit	7659452
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2852191
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4924733
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5406000
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9561821
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4167821
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4677530
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6406285
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9307012
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25

Files In Submission

Name	View Source	Status
0001410578-24-000201-index-headers.html	Edgar Link	pending
0001410578-24-000201-index.html	Edgar Link	pending
0001410578-24-000201.txt	Edgar Link	pending
0001410578-24-000201-xbrl.zip	Edgar Link	pending
ctso-20231231.xsd	Edgar Link	pending
ctso-20231231x10k.htm	Edgar Link	pending
ctso-20231231xex21d1.htm	Edgar Link	pending
ctso-20231231xex23d1.htm	Edgar Link	pending
ctso-20231231xex31d1.htm	Edgar Link	pending
ctso-20231231xex31d2.htm	Edgar Link	pending
ctso-20231231xex32d1.htm	Edgar Link	pending
ctso-20231231xex32d2.htm	Edgar Link	pending
ctso-20231231xex97d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
ctso-20231231_cal.xml	Edgar Link	unprocessable
ctso-20231231_def.xml	Edgar Link	unprocessable
ctso-20231231_lab.xml	Edgar Link	unprocessable
ctso-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctso-20231231x10k_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2024 Q1 Form 10-K Financial Statement

#000141057824000201 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2024 Q1 Form 10-K Financial Statement

#000141057824000201 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso